Daré Bioscience Inc (DARE)
NASDAQ:DARE
Top Page
Daré Bioscience
(NASDAQ:DARE)
Select Model
Select Model
Rating:48Neutral
Price Target:
$2.00
▲(17.65% Upside)
Action:ReiteratedDate:03/31/26
The score is primarily held down by weak financial performance characterized by large losses, heavy cash burn, and balance-sheet instability. Offsetting factors include improving near-term technical positioning and a constructive earnings-call outlook with upcoming launches and grant-supported programs, while valuation remains challenged due to negative earnings and recent financing adds some funding support but with dilution risk.
Positive Factors
Commercial pipeline and multi-path go-to-market
Daré’s dual-path commercialization strategy (503B compounding plus pursuing FDA pathways and consumer-branded routes) and scheduled launches create multiple, durable commercialization channels. This reduces single-path regulatory timing risk and supports staggered revenue generation as products move from launch to scale.
Negative Factors
Severe negative operating and free cash flow
Extremely negative operating and free cash flows signal persistent cash burn and reliance on external financing. This structural cash-flow weakness materially increases execution risk for multi-year development and commercialization plans and forces recurring capital raises that dilute shareholders and divert management attention.
Read all positive and negative factors
Positive Factors
Negative Factors
Commercial pipeline and multi-path go-to-market
Daré’s dual-path commercialization strategy (503B compounding plus pursuing FDA pathways and consumer-branded routes) and scheduled launches create multiple, durable commercialization channels. This reduces single-path regulatory timing risk and supports staggered revenue generation as products move from launch to scale.
Read all positive factors
Daré Bioscience (DARE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$26.94M
Dividend YieldN/A
Average Volume (3M)170.74K
Price to Earnings (P/E)―
Beta (1Y)1.08
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees21
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.03
Shares Outstanding14,559,502
10 Day Avg. Volume281,723
30 Day Avg. Volume170,743
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)75.90
Price to Sales (P/S)209.43
P/FCF Ratio-0.02
Enterprise Value/Market Cap-818.18
Enterprise Value/Revenue-21.39K
Enterprise Value/Gross Profit7.75K
Enterprise Value/Ebitda1.95K
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.23
Revenue Forecast (FY)$28.84M
Daré Bioscience Business Overview & Revenue Model
Company Description
Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, fertility, and sexual a...
How the Company Makes Money
Daré Bioscience generates revenue primarily through product-related commercialization arrangements and collaboration-related income rather than broad, direct product sales. Its revenue model has historically included (1) licensing and partnering: ...
Daré Bioscience Earnings Call Summary
Earnings Call Date:Nov 13, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:May 19, 2026
Earnings Call Sentiment Positive
The earnings call highlighted significant advancements in Daré Bioscience's commercial and clinical pipeline, supported by strong financial management and strategic partnerships. However, increased expenses and limitations in capital generation were noted concerns. Overall, the positive developments in the product pipeline and financial position outweigh the challenges.Positive Updates
Commercial Launch of DARE to PLAY Sildenafil Cream
Daré Bioscience is on track to launch DARE to PLAY Sildenafil Cream through a 503B outsourcing facility by the end of the year, marking a major milestone for women's sexual health.
Negative Updates
Increased G&A Expenses
General and administrative expenses increased to $2.5 million, up from $2 million in the same period last year, due to professional services and commercial readiness expenses.
Read all updates
Q3-2025 Updates
Positive
Negative
Commercial Launch of DARE to PLAY Sildenafil Cream
Daré Bioscience is on track to launch DARE to PLAY Sildenafil Cream through a 503B outsourcing facility by the end of the year, marking a major milestone for women's sexual health.
Read all positive updates
Company Guidance
In the recent conference call, Daré Bioscience provided detailed guidance on its strategic initiatives and financial performance for the third quarter of 2025. The company emphasized its dual path strategy, focusing on both the commercialization of proprietary formulations through 503B compounding and the pursuit of FDA approval, as well as advancing select solutions as branded consumer health products without prescription requirements. Notably, Daré is on track to launch DARE to PLAY Sildenafil Cream through a 503B outsourcing facility by the end of the year, marking a significant milestone in women's sexual health. The company is also preparing to introduce DARE to RESTORE vaginal probiotic products in early 2026 and DARE to RECLAIM, a hormone therapy ring, in early 2027. Financially, Daré ended the quarter with $23 million in cash and cash equivalents and received $18.7 million from common stock sales and $7.3 million in grant payments. G&A expenses increased to $2.5 million, while R&D expenses decreased by 56% due to increased nondilutive funding. The company's pipeline includes grant-funded programs targeting contraception, HPV infection, and preterm birth, underscoring its commitment to addressing unmet needs in women's health.Daré Bioscience Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
34
Negative
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.03M | 9.78K | 2.81M | 10.00M | 0.00 |
| Gross Profit | -1.42M | -14.30M | -18.83M | -20.14M | -100.00K |
| EBITDA | -11.40M | -23.41M | -30.70M | -31.36M | -39.04M |
| Net Income | -13.40M | -4.05M | -30.16M | -30.95M | -38.70M |
Balance Sheet | |||||
| Total Assets | 32.47M | 22.10M | 21.28M | 43.83M | 55.81M |
| Cash, Cash Equivalents and Short-Term Investments | 24.71B | 15.70M | 10.48M | 34.67M | 51.67M |
| Total Debt | 2.66B | 1.30M | 1.40M | 488.74K | 270.55K |
| Total Liabilities | 29.63M | 28.11M | 26.33M | 32.71M | 17.05M |
| Stockholders Equity | 2.84M | -6.01M | -5.05M | 11.11M | 38.75M |
Cash Flow | |||||
| Free Cash Flow | -10.27B | 4.82M | -39.49M | -18.15M | -28.78M |
| Operating Cash Flow | -9.89B | 5.39M | -38.86M | -18.09M | -28.76M |
| Investing Cash Flow | -385.28M | -573.05K | -629.43K | -63.07K | -14.52K |
| Financing Cash Flow | 19.28B | 433.83K | 15.64M | 1.34M | 75.85M |
Daré Bioscience Technical Analysis
Positive
1.70
Price Trends
1.64
Positive
1.80
Positive
2.00
Negative
Market Momentum
0.06
Negative
62.74
Neutral
81.52
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DARE, the sentiment is Positive. The current price of 1.7 is above the 20-day moving average (MA) of 1.57, above the 50-day MA of 1.64, and below the 200-day MA of 2.00, indicating a neutral trend. The MACD of 0.06 indicates Negative momentum. The RSI at 62.74 is Neutral, neither overbought nor oversold. The STOCH value of 81.52 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DARE.
Daré Bioscience Risk Analysis
Daré Bioscience disclosed 82 risk factors in its most recent earnings report. Daré Bioscience reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Daré Bioscience Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $26.94M | -16.10 | 274.47% | ― | ― | ― | |
47 Neutral | $25.77M | -0.46 | -49.73% | ― | ― | -0.50% | |
46 Neutral | $29.80M | -0.82 | -87.18% | ― | ― | 38.42% | |
43 Neutral | $14.95M | -0.72 | -364.96% | ― | -48.74% | 89.18% | |
41 Neutral | $25.49M | -1.76 | ― | ― | ― | 31.09% |
* Healthcare Sector Average
DARE
Daré Bioscience
1.85
-1.04
-35.99%
HIND
Vyome Holdings
2.13
-54.53
-96.24%
LNAI
Lunai Bioworks
0.36
-3.27
-90.15%
PASG
Passage Bio
9.29
2.05
28.31%
NRSN
Neurosense Therapeutics Ltd.
0.72
-0.27
-27.02%
BOLD
Boundless Bio Inc.
1.15
-0.04
-3.36%
Daré Bioscience Corporate Events
Private Placements and Financing
Daré Bioscience Completes Regulation A Preferred Stock Offering
Positive
Mar 17, 2026
On March 16, 2026, Daré Bioscience, Inc. closed a previously announced Regulation A offering of investor units priced at $5.00 each, with each unit consisting of one share of Series A Convertible Preferred Stock and two warrants to purchase c...
Private Placements and FinancingRegulatory Filings and Compliance
Daré Bioscience Completes Second Closing of Regulation A Offering
Positive
Mar 9, 2026
On March 6, 2026, Daré Bioscience completed the second closing of its previously announced Regulation A offering of Investor Units, each priced at $5.00 and consisting of one share of Series A Convertible Preferred Stock and two Investor Warr...
Business Operations and StrategyRegulatory Filings and Compliance
Daré Bioscience Updates Investor Presentation Under Regulation FD
Neutral
Mar 2, 2026
On March 2, 2026, Daré Bioscience, Inc. made an updated corporate presentation available to investors through the investors section of its website, providing refreshed information on the company for the market. The presentation was simultaneo...
Private Placements and FinancingRegulatory Filings and Compliance
Daré Bioscience Launches Regulation A Preferred Unit Offering
Positive
Jan 29, 2026
On January 23, 2026, Daré Bioscience filed a Certificate of Designation in Delaware creating a new Series A Convertible Preferred Stock, setting its liquidation preference at $5.00 per share, ranking it senior to common stock, eliminating div...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.